FDA-Approved First-Line Medications for Fibromyalgia
The three FDA-approved medications for fibromyalgia are pregabalin, duloxetine, and milnacipran, with duloxetine 60 mg daily being the preferred initial choice based on superior efficacy for pain and depression, better real-world adherence, and comparable tolerability. 1, 2, 3
Specific Dosing Recommendations
Duloxetine (Preferred First-Line)
- Starting dose: 30 mg once daily for 1 week, then increase to 60 mg once daily
- Maintenance dose: 60 mg once daily (most patients)
- Maximum dose: 120 mg once daily if needed for severe pain or depression
- Duloxetine 120 mg showed the highest efficacy for pain reduction (SMD -0.33) and depression (SMD -0.25) compared to placebo 2
- Real-world data shows 91% of patients achieve label-recommended maintenance dosing, with mean treatment duration of 205 days—significantly longer than other options 1
Pregabalin (Alternative First-Line)
- Starting dose: 150 mg daily in 2-3 divided doses
- Titration: Increase to 300 mg daily within 1 week based on efficacy and tolerability
- Maintenance dose: 300-450 mg daily in 2-3 divided doses
- Maximum dose: 450 mg daily (600 mg rarely needed)
- Critical pitfall: Real-world prescribing shows 35% of patients receive subtherapeutic starting doses and only 27% achieve recommended maintenance dosing 1, which likely explains treatment failures
Milnacipran (Alternative First-Line)
- Starting dose: 12.5 mg once daily on day 1
- Titration: Increase to 12.5 mg twice daily (days 2-3), then 25 mg twice daily (days 4-7)
- Maintenance dose: 50 mg twice daily (100 mg total daily)
- Maximum dose: 100 mg twice daily (200 mg total daily) if needed
- 80% of patients achieve recommended maintenance dosing in real-world practice 1
Evidence-Based Selection Algorithm
Step 1: Assess dominant symptom profile
- Pain + depression predominant → Duloxetine 60-120 mg daily 2
- Pain + sleep disturbance predominant → Pregabalin 300-450 mg daily 2
- Pain + fatigue predominant → Milnacipran 100-200 mg daily 4
Step 2: Evaluate treatment response at 8-12 weeks
- Only 1 in 10 patients achieves ≥50% pain reduction with any single agent 3
- If inadequate response, switch to alternative FDA-approved agent rather than combining
- Evidence supports efficacy only for 4-12 weeks; no data beyond 6 months 3
Critical Evidence Considerations
The 2024 Cochrane overview 3 provides the most comprehensive assessment, confirming moderate-to-good evidence only for duloxetine, milnacipran, and pregabalin. All three medications show modest efficacy with approximately 1 in 10 patients experiencing substantial (≥50%) pain relief. Serious adverse events occur at rates similar to placebo across all three agents 3.
The 2022 network meta-analysis 2 demonstrates duloxetine 120 mg ranks highest for pain and depression, while amitriptyline (off-label) ranks highest for sleep and fatigue but is not FDA-approved. This supports duloxetine as the most versatile first-line option.
Important Caveats
- No evidence exists identifying which patients will respond to specific medications 3
- Acceptability (dropout rates) is inferior to placebo for all agents except amitriptyline 2, emphasizing the need for realistic patient expectations
- Real-world underdosing is common, especially with pregabalin 1, leading to preventable treatment failures
- The 2017 EULAR guidelines 5 emphasize exercise as the only "strong for" recommendation, with pharmacotherapy rated "weak for" and reserved for severe pain or sleep disturbance unresponsive to non-pharmacological approaches
Recent Development
Sublingual cyclobenzaprine (TNX-102 SL) received FDA approval in August 2025 6, 7, representing the first new fibromyalgia medication in over 15 years. However, it should be considered second-line given limited long-term data and primarily local oral adverse effects. Dosing is 2.8 mg sublingually at bedtime, targeting sleep-related pain mechanisms 7.